



*Imate*

16368  
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Keith L. Black

Serial No.: 09/615,854

Filed: July 14, 2000

For: Method for Using Potassium Channel Activation  
for Delivering A Medicant to An Abnormal Brain  
Brain Region and/or A Malignant Tumor

Art Unit: 1636

INFORMATION DISCLOSURE STATEMENT

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Arlington, VA 22313-1450

February 17, 2004

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicants cite the publications listed on the accompanying PTO-1449. Copies of all listed references are enclosed. The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under the applicable statutes, Rules of Practice in patent cases, or otherwise. Applicants calls the Examiner's attention to the fact that a Request for Continued Examination (RCE) was filed in this case on January 20, 2004 under 37 C.F.R §1 114.

Applicant has also enclosed the required fee of \$180.00 as specified under 37 CFR §1.17(p). If the Examiner determines an additional fee is required, the Commissioner is authorized to charge any requisite fees associated with this paper to Deposit Account No. 11-0980.

02/23/2004 CCHAU1 00000115 09615854

01 FC:1806

180.00 0P

Respectfully submitted,

*Rebecca Kaufman*

Rebecca Kaufman  
Reg. No. 44,819


King & Spalding  
191 Peachtree Street, N.E., 45<sup>th</sup> Floor,  
Atlanta, GA 30303  
404.572.4600 (main); 404.572.5145 (fax)



Serial No. 09/615,854

**CERTIFICATE OF MAILING (37 CFR 1.8a)**

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

  
Vickie A. Halstead

Date: February 17, 2004

Attorney Docket No.: BBB102

Please type a plus sign (+) inside this box ☐Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

Application Number	09/615,854
Filing Date	July 14, 2000
First Named Inventor	Keith L. Black
Group Art Unit	1636
Examiner Name	Qian, C.X.
Attorney Docket Number	BBB

Sheet	1	of	5
-------	---	----	---

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	AA	5,518,499		Agar	05-21-1996	
	AB	5,767,160		Kaesemeyer	06-16-2002	
	AC	6,417,207		Garvey et al.	07-09-2002	
	AD	20020143188		Garvey et al.	10-03-2002	

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	AE	ABDUL, M. and Hoosein, N.M., <i>Expression and activity of potassium ion channels in human prostate cancer</i> , <u>Cancer Letters</u> 186:99-106 (2002).	
	AF	ABDUL, M., and Hoosein, N.M., <i>Voltage-gated potassium channel ions in human colon cancer</i> , <u>Oncology Rep.</u> 9:961-964 (2002).	
	AG	ABDUL, M. et al., <i>Activity of potassium channel-blockers in breast cancer</i> , <u>Anticancer Research</u> , 23(4):3347-51 (2003).	
	AH	ASOTRA, Kamlesh et al., <i>Measurement of Blood-Brain and Blood-Tumor Barrier permeabilities with [<sup>14</sup>C]-Labeled Tracers</i> , <u>Methods in Molecular Medicine</u> , Vol. 89: The Blood-Brain Barrier: Biology and Research Protocols, 177-190.	
	AI	BABA, Takehiko et al., <i>Intracarotid Infusion of Leukotriene C<sub>4</sub> Selectively Increases Blood-Brain Barrier Permeability after Focal Ischemia in Rats</i> , <u>Journal of Cerebral Blood Flow and Metabolism</u> , 11:638-643 (1991).	
	AJ	BARNA, M., et al., <i>Activation of type III nitric oxide synthase in astrocytes following a neurotropic viral infection</i> , <u>Virology</u> , 223: 331-343 (1996).	
	AK	BARTUS, Raymond T. et al., <i>Use of Cereport™ (RMP-7) to Increase Delivery of Carboplatin to Gliomas: Insight and Parameters for Intracarotid Infusion Via a Single-Lumen Cannula</i> , <u>Drug Delivery</u> , 6:15-21 (1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> 		Application Number	09/615,854
		Filing Date	July 14, 2000
		First Named Inventor	Keith L. Black
		Group Art Unit	1636
		Examiner Name	Qian, C.X.
		Attorney Docket Number	BBB
Sheet	of	5	

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	BA	BLACK, Keith L., <i>Biochemical opening of the blood-brain barrier</i> , <u>Advance Drug Delivery Reviews</u> , 15:37-52 (1995).	
	BB	BLACK, Keith L., <i>Imaging and Drug Delivery to Tumor-infiltrated Brain</i> , Clinical Neurosurgery, Chapter 30:563-572.	
	BC	BLACK, Keith L. et al., <i>Increased opening of blood-tumour barrier by leukotriene C<sub>4</sub> is dependent on size of molecules</i> , <u>Neurological Research</u> , 14: 402-404, (1992).	
	BD	BLACK, Keith L. et al., <i>Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium<sup>68</sup> ethylenediamine tetraacetic acid inot humon gliomas</i> , <u>J. Neurosurg.</u> , 86:603-609 (1997).	
	BE	BLACK, Keith, et al. <i>Leukotriene C<sub>4</sub> Receptors in Isolated Brain Capillaries</i> , <u>Advances in Prostaglandin Thromboxane, and Leukotriene Research</u> , 17:508-511 (1987).	
	BF	BLACK, Keith et al., <i>Leukotrienes Increase Blood-Brain Barrier permeability Following Intraparenchymal Injections in Rats</i> , <u>Annals of Neurology</u> , 18:3 349-351 (1985).	
	BG	BLACK, Keith L., <i>Selective Opening of Blood-Brain Barrier for Drug Delivery to Brain Tumors</i> , <u>Perspectives in Neurological Surgery</u> , 4:1 97-104 (1993).	
	BH	BOJE, K.M., <i>Inhibition of nitric oxide synthase attenuates blood-brain barrier disruption during experimental meningitis</i> , <u>Brain Research</u> , 720:75-83 (1996).	
	BI	BRANDT, L., et al., <i>Effects of topical application of calcium antagonist (nifedipine) on feline cortical pial microvasculature under normal conditions and in focal ischemia</i> , <u>Journal of Cerebral Blood Flow and Metabolism</u> , 3:44-50 (1983).	
	BJ	BRIONI, J.D., et al., <i>Activators of soluble guanylate cyclase for treatment of male erectile dysfunction</i> , <u>International Journal of Impotence Research</u> , 14:8-14 (2002).	
	BK	CHANDRAN, S., et al., <i>Nitric oxide: concepts, current perspectives and future therapeutic implications</i> , <u>Indian Journal of Pharmacology</u> , 30:351-366 (1998).	
	BL	CHI, O.Z., et al. <i>Effect of inhibition of nitric oxide synthase on blood-brain barrier transport in focal cerebral ischemia</i> , <u>Pharmacology</u> , 48:367-373 (1994).	
	BM	CHIO, Chung-Ching et al., <i>Selective blood-tumor barrier disruption by leukotrienes</i> , <u>J. Neurosurg.</u> , 77:407-410 (1992).	
	BN	CLOUGHESY, T.F., et al., <i>Pharmacological blood-brain barrier modification for selective drug delivery</i> , <u>Journal of Neuro-Oncology</u> , 26:125-132 (1995).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> FEB 19 2004 (Use as many sheets as necessary)		Application Number	09/615,854
		Filing Date	July 14, 2000
		First Named Inventor	Keith L. Black
		Group Art Unit	1636
		Examiner Name	Qian, C.X.
		Attorney Docket Number	BBB
Sheet 1 of 5			

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	CA	CLOUGHESY, Timothy F. et al., <i>Intra-arterial carboplatin chemotherapy for brain tumors: A dose escalation study based on cerebral blood flow</i> , <u>Journal of Neuro-Oncology</u> , 35:121-131 (1997).	
	CB	CLOUGHESY, Timothy F. et al., <i>Intra-arterial Cereport (RMP-7) and Carboplatin: A Dose Escalation Study of Recurrent Malignant Gliomas</i> , <u>Neurosurgery</u> , 44:2 270-279 (1999).	
	CC	ELLIOTT, Peter J., et al., <i>Unlocking the Blood-Brain Barrier: A Role for RMP-7 in Brain Tumor Therapy</i> , <u>Experimental Neurology</u> , 141: 214-224 (1996).	
	CD	HASHIZUME, Kazuhiro, et al., <i>Increased Endothelial Vesicular Transport Correlates with Increased Blood-Tumor Barrier Permeability Induced by Bradykinin and Leukotriene C<sub>4</sub></i> , <u>Journal of Neuropathology and Experimental Neurology</u> , 61:8 725-735 (2002).	
	CE	HONGLI, X., et al., <i>Opening blood-brain-barrier by intracarotid infusion of papaverine in treatment of malignant cerebral glioma</i> , <u>Chinese Medical Journal</u> , 111(8):751-753 (1998).	
	CF	HURST, R.D., et al., <i>Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier</i> , <u>Journal of Cellular Physiology</u> , 167:89-94 (1996).	
	CG	INAMURA, T., et al., <i>Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma</i> , <u>Neurological Research</u> , 16:125-128 (1994).	
	CH	INAMURA, T., et al., <i>Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors</i> , <u>J Neurosurg</u> , 81:752-758 (1994).	
	CI	INAMURA, Takanori, et al., <i>Bradykinin Selectively Opens Blood-Tumor Barrier in Experimental Brain Tumors</i> , <u>Journal of Cerebral Blood Flow and Metabolism</u> , 14:862-870 (1994).	
	CJ	JANIGRO, D., et al., <i>Regulation of blood-brain barrier endothelial cells by nitric oxide</i> , <u>Circulation Research</u> , 75:528-528 (1994).	
	CK	LIU, Y., et al., <i>Repeated, short-term ischemia augments bradykinin-mediated opening of the blood-tumor barrier in rats with RG2 glioma</i> , <u>Neurological Research</u> , 23:631-639 (2001).	
	CL	LIU, Yunhui et al., <i>Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors</i> , <u>Neurological Research</u> , 23:379-387 (2001).	
	CM	KING, Wesley A., et al., <i>Intracarotid Infusion of Leukotriene C<sub>4</sub> Increases Blood-Tumor Barrier Permeability in Experimental Rat Brain Tumors</i> , <u>Neurological Surgery Surgical Forum</u> , Volume XL: 490-493 (1989).	
	CN	MATSUKADO, K., et al., <i>Steroids Decrase Uptake of Carboplatin in Rat Gliomas - Uptake improved by Intracarotid Infusion of Bradykinin Analog, RMP-7</i> , <u>Acta Neurochir</u> , 70: 159-161 (1997).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

FEB 19 2004

Use as many sheets as necessary)

Sheet

of

5

**Complete if Known**

Application Number	09/615,854
Filing Date	July 14, 2000
First Named Inventor	Keith L. Black
Group Art Unit	1636
Examiner Name	Qian, C.X.
Attorney Docket Number	BBB

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	DA	MATSUKADO, Koichiro, et al., <i>Enhanced Tumor Uptake of Carnoplatin and Survival in glioma-bearing Rats by Intracarotid Infusion of Bradykinin Analog, RMP-7</i> , <u>Neurosurgery</u> , 39:1 125-134 (1996).	
	DB	MATSUKADO, Koichiro, et al., <i>Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas</i> , <u>Brain Research</u> , 792 10-15 (1998).	
	DC	MAYHAN, W.G., <i>Role of nitric oxide in histamine-induced increases in permeability of the blood-brain barrier</i> , <u>Brain Research</u> , 743:70-76 (1996).	
	DD	MAYHAN, W.G., et al., <i>Glutamate-induced disruption of the blood-brain barrier in rats</i> , <u>Stroke</u> , 27:965-970 (1996).	
	DE	NAKANO, S., et al., <i>Increased brain microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide</i> , <u>Cancer Research</u> , 56:4027-4031 (1996).	
	DF	NAKANO, Shin, et al. <i>Enhanced cytokines delivery and intercellular adhesion molecule 1 (ICAM-1) expression in glioma by intracarotid infusion of bradykinin analog, RMP-7</i> , <u>Neurological Research</u> , 19: 501-508 (1997).	
	DG	NINGARAJ, N.S., et al., <i>Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels</i> , <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 301: 838-851 (2002).	
	DH	NINGARAJ, Nagendra S., et al., <i>Calcium-Dependent Potassium Channels as a Target Protein for Modulation of the Blood-Brain Tumor Barrier</i> , <u>Drug News Perspect</u> , 16(5) 291-298 (2003).	
	DI	NOMURA, Tomojior, et al., <i>Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors</i> , <u>Brain Research</u> , 659: 62-66 (1994).	
	DJ	PARDRIGE, W., et al., <i>Blood-brain barrier and new approaches to drug delivery</i> , <u>West J Med</u> , 156:281-286 (1992).	
	DK	RILEY, M. Gary I., et al., <i>Intra-arterial administration of carboplatin and the blood brain barrier permeabilizing agent, RMP-7: A toxicologic evaluation in swine</i> , <u>Journal of Neuro-Oncology</u> , 36: 167-178 (1998).	
	DL	SHUKLA, A., et al., <i>Nitric oxide-dependent blood-brain barrier permeability alteration in the rat brain</i> , <u>Experientia</u> , 52:136-140 (1996).	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <b>FEB 19 2004</b> (Use as many sheets as necessary)		Application Number	09/615,854
		Filing Date	July 14, 2000
		First Named Inventor	Keith L. Black
		Group Art Unit	1636
		Examiner Name	Qian, C.X.
		Attorney Docket Number	BBB
Sheet		of	5

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	EA	SUGITA, M., et al., <i>Cyclic GMP-specific phosphodiesterase inhibition and intracarotid bradykinin infusion enhances permeability in brain tumors</i> , <u>Cancer Research</u> , 58:914-920 (1998).	
	EB	SUGITA, Masoa, et al., <i>Nitric oxide and cyclic GMP attenuate sensitivity of the blood-tumor barrier permeability to bradykinin</i> , <u>Neurological Research</u> , 20: 559-563 (1998).	
	EC	TAKAYASU, M., et al., <i>Effects of calcium antagonists on intracerebral penetrating arterioles in rats</i> , <u>J Neurosurg</u> , 69:104-109 (1988).	
	ED	UCHIDA, M., et al., <i>Overexpression of bradykinin type 2 receptors on glioma cells enhances bradykininmediated blood-brain tumor varrier permeability increase</i> , <u>Neurological Research</u> , 24:739-745 (2002).	
	EE	WOODFORD, K.A. et al., <i>Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest in human breast cancer cells in tissue culture</i> , <u>J Cell Physiol.</u> 162(2):163-71 (1995).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.